The company’s consolidated revenue stood at Rs703.91cr, down 0.35% yoy and 15.83% qoq.
New Delhi, February 06, 2018:
Glaxosmithkline Pharma Ltd Q3FY18
Consolidated Results Q3FY18: (Rs. in crore)
| Q3FY18 | YoY (%) | |
|---|---|---|
| Revenue | 703.91 | |
| EBITDA | 141.81 | 172.1 |
| EBITDA Margin (%) | 20.2 | 1,277 |
| Net Profit (adjusted) | 89.69 | 69.4 |
GlaxoSmithKline Pharmaceuticals reported flat growth in its revenue to Rs703.9cr for Q3FY18 vs. Rs706.4cr in Q3FY17. EBITDA grew by 172% to Rs142cr from Rs52.1cr in Q3FY17. Profit after tax grew 69.4% to Rs89.7cr from Rs52.9cr in Q3FY17. The results for Q3FY17 were impacted due to the effect of demonetization, hence are not comparable with Q3FY18.
- Company has indicated that the underlying performance, excluding GST impact and prior year disposals, is supported by high single to double digit volume growth of its key brands and therapy areas.
- EBITDA margin improved due to enhanced product mix, stock management and cost optimization.
- Company has received the money from the disposal of its 60-acre Thane land. The transfer of this land is subject to clearance of statutory and other permissions.
- Company recorded a tax rate of 36% in the quarter vs. 32% in Q3FY17 and 35% in Q2FY18.
Technical View:
Glaxosmithkline Pharmaceuticals Ltd ended at Rs. 2,460, up by 20.75 points or 0.85% from its previous closing of Rs. 2,439.25 on the BSE.
The scrip opened at Rs. 2,435 and touched a high and low of Rs. 2,490 and Rs. 2,422 respectively. A total of 12,186(NSE+BSE) shares were traded on the counter. The stock traded below its 200 DMA.
